Najahi-Missaoui Wided, Dailey Harry A
Biomedical and Health Sciences Institute, University of Georgia, A222 Life Sciences Bldg, Athens GA 30602, USA.
Blood. 2005 Aug 1;106(3):1098-104. doi: 10.1182/blood-2004-12-4661. Epub 2005 Apr 14.
Mutations resulting in diminished activity of the dimeric enzyme ferrochelatase are a prerequisite for the inherited disorder erythropoietic protoporphyria (EPP). Patients with clinical EPP have only 10% to 30% of normal levels of ferrochelatase activity, and although many patients with EPP have one mutant allele and one "low-expression" normal allele, the possibility remains that, for some, low ferrochelatase activity may result from an EPP mutation that has an impact on both subunits of the wild-type/mutant heterodimer. Here we present data for 12 ferrochelatase wild-type/EPP mutant heterodimers showing that some mutations result in heterodimers with the residual activity anticipated from individual constituents, whereas others result in heterodimers with significantly lower activity than would be predicted. Although the data do not allow an a priori prediction of heterodimeric residual activity based solely on the in vitro activity of EPP homodimers or the position of the mutated residue within ferrochelatase, mutations that affect the dimer interface or [2Fe-2S] cluster have a significantly greater impact on residual activity than would be predicted. These data suggest that some EPP mutations may result in clinically overt EPP in the absence of a low-expression, wild-type allele; this is of potential significance for genetic counseling of patients with EPP.
导致二聚体酶铁螯合酶活性降低的突变是遗传性疾病红细胞生成性原卟啉症(EPP)的先决条件。临床EPP患者的铁螯合酶活性仅为正常水平的10%至30%,尽管许多EPP患者有一个突变等位基因和一个“低表达”正常等位基因,但对于一些患者来说,铁螯合酶活性低仍有可能是由一个对野生型/突变型异二聚体两个亚基都有影响的EPP突变导致的。在此,我们展示了12种铁螯合酶野生型/EPP突变型异二聚体的数据,表明一些突变导致的异二聚体具有单个成分预期的残余活性,而其他突变导致的异二聚体活性明显低于预期。尽管这些数据不允许仅基于EPP同二聚体的体外活性或铁螯合酶内突变残基的位置对异二聚体残余活性进行先验预测,但影响二聚体界面或[2Fe-2S]簇的突变对残余活性的影响比预期的要大得多。这些数据表明,一些EPP突变可能在没有低表达野生型等位基因的情况下导致临床上明显的EPP;这对EPP患者的遗传咨询具有潜在意义。